IgA nephropathy, often abbreviated IgAN, is the most common primary glomerular disease worldwide and a leading cause of kidney failure in young and middle-aged adults. The disease arises from a subtle but destructive immunological misstep: the body produces abnormally high quantities of galactose-deficient IgA1, a poorly glycosylated version of a common antibody. These aberrant molecules accumulate in the bloodstream, provoke the formation of immune complexes, and ultimately deposit in the glomeruli, the delicate filtering units of the kidney. The resulting inflammation and scarring progressively erode the kidney’s ability to filter waste, a process that can unfold silently over decades. Many patients reach advanced chronic kidney disease or dialysis before they fully grasp how much function they have lost, a reality that has made IgAN a notorious ‘silent’ threat in nephrology.

For decades, treatment options were blunt. Non-specific immunosuppression with systemic corticosteroids could slow the disease, but at the cost of exposing the entire body to high steroid doses, with well-documented risks including infections, diabetes, weight gain, and cardiovascular complications. The intellectual breakthrough behind Nefecon was anatomical rather than chemical. Recognizing that mucosal immunity, particularly in the gut-associated lymphoid tissue concentrated near the ileocecal region, drives much of the overproduction of galactose-deficient IgA1, researchers engineered a capsule coated to withstand stomach acid and release budesonide precisely where Peyer’s patches are densest. The drug then exerts a local immunomodulatory effect on the lymphoid tissue that seeds the disease, while first-pass hepatic metabolism limits systemic steroid exposure. It is, in effect, a precision strike on the disease’s immunological engine room.

The concept was validated in controlled settings by the phase 2b NEFIGAN trial and the pivotal phase 3 NefIgArd program, which demonstrated statistically significant proteinuria reduction and, in two-year results, meaningful preservation of estimated glomerular filtration rate. But clinical trials enroll selected patients under idealized conditions, and regulators and clinicians alike have increasingly demanded confirmation that the benefit translates to the messy, heterogeneous reality of routine practice. The Xinjiang study was designed to address exactly this gap. Between September 2024 and March 2025, the investigators consecutively enrolled 28 patients with biopsy-confirmed primary IgAN who had been treated with Nefecon for more than nine months, collecting standardized data on demographics, laboratory outcomes, and adverse events in a retrospective real-world cohort.

The headline results are dramatic. After nine months of therapy, mean proteinuria fell from 1.7 plus or minus 1.2 grams per day to 0.6 plus or minus 0.5 grams per day, a reduction of 55.8 percent. That figure matters enormously because proteinuria is one of the most powerful modifiable predictors of long-term renal prognosis in IgAN; cohort studies have repeatedly shown that each gram of persistent protein in the urine compounds the risk of progression toward kidney failure. Equally notable was the change in kidney function itself. Estimated glomerular filtration rate, the standard measure of how well the kidneys filter, improved from 80.3 to 86.2 mL/min/1.73 m2, a gain of roughly five percent. Any functional improvement during active autoimmune disease is unusual and suggests the treatment is not merely suppressing symptoms but genuinely interrupting inflammatory injury.

Perhaps the most clinically provocative finding concerns baseline proteinuria. Patients entered the study across a range of proteinuria levels, and Nefecon appeared to deliver renal protection regardless of where a patient started, with signals suggesting greater benefit when treatment was initiated earlier in the disease course. This challenges a lingering clinical conservatism in which the most aggressive therapies are reserved for patients already showing heavy proteinuria and declining function. If low-level proteinuria is treated as a warning sign rather than a tolerated quirk, the window in which kidney tissue can still be rescued widens considerably. The study’s authors suggest that this supports a strategy of early intervention following diagnosis, an approach now echoed in evolving international treatment guidance, including the KDIGO 2025 clinical practice guideline for IgA nephropathy.

Safety data from the cohort will reassure clinicians who have watched the therapeutic landscape expand rapidly. Seventeen of the 28 patients, or 60.7 percent, experienced at least one adverse event, but the spectrum was mild and predictable for a locally targeted steroid. The most common event was acne, affecting 21.4 percent of patients. Crucially, no severe adverse events and no treatment-related deaths were observed, and the tolerated profile contrasts sharply with the serious corticosteroid toxicities documented with systemic steroid regimens in earlier IgAN trials. Because Nefecon releases budesonide in the distal small intestine and is largely cleared on first pass through the liver, systemic exposure remains a fraction of what conventional oral prednisone produces, and this real-world dataset supports that pharmacokinetic advantage in routine use.

The study’s significance extends beyond a single drug. IgAN has recently become one of the most dynamic fields in nephrology, with endothelin receptor antagonists, SGLT2 inhibitors, and complement-targeted therapies all entering the treatment algorithm alongside Nefecon. Real-world evidence like this cohort study functions as a crucial bridge between regulatory trials and everyday clinical decision-making, confirming that the antiproteinuric effects seen in the randomized NefIgArd population, including the mainland China substudy, reproduce in a broader, unselected patient group. It also provides nephrologists with practical dosing-and-response expectations: a majority proteinuria reduction at nine months is a realistic and clinically meaningful benchmark when patients are treated under standard care conditions.

Limitations remain, and the investigators are appropriately measured about them. The cohort is small, retrospective, and drawn from a single center, and nine months, while sufficient to capture established treatment response, cannot reveal whether functional gains persist after therapy stops or whether the drug alters the long-term risk of kidney failure. These caveats notwithstanding, the consistency of the findings with the randomized trial evidence strengthens the case that Nefecon has earned a genuine place in routine care. For the millions of people living with IgA nephropathy worldwide, the message from this study is quietly radical: the disease can be attacked at its immunological source, the kidneys can be protected before they are irreversibly damaged, and treatment can begin early, safely, and effectively. As real-world experience accumulates, the era of watchful waiting in IgAN is steadily giving way to one of early, targeted intervention.

Subject of Research: Real-world effectiveness and safety of targeted-release budesonide (Nefecon) in primary IgA nephropathy across baseline proteinuria levels

Article Title: Effectiveness and Safety of Nefecon in Primary IgA Nephropathy Across Different Baseline Proteinuria Levels: A Real-World Study

Article References: Suolinge, C., Dema, C., Wu, X., Jiang, B., Lu, C., & Li, J. (2026). Effectiveness and Safety of Nefecon in Primary IgA Nephropathy Across Different Baseline Proteinuria Levels: A Real-World Study. Advances in Therapy. https://doi.org/10.1007/s12325-026-03784-0

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03784-0

Keywords: IgA nephropathy, Nefecon, targeted-release budesonide, proteinuria, kidney function, estimated glomerular filtration rate, real-world evidence, galactose-deficient IgA1, chronic kidney disease, early intervention, nephrology, autoimmune kidney disease